Replies to post #205723 on Biotech Values

[Bickema]

RVNC - with all the drug pricing witch hunts going on and the damning DOJ investigation you would figure big pharma would be looking at Revance as an alternative option to add future revenues in a space more predictable and less hostile.

[DewDiligence]

RVNC—Update on size of phase-3 efficacy trials in glabellar lines:

$RVNC —So less time 2enroll patients, which makes reporting of topline data in 4Q17 more realistic.

— Roy Friedman (@DewDiligence) November 21, 2016